Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor Meeting Abstract
| Authors: | De Bono, J. S.; Fizazi, K.; Saad, F.; Taplin, M. E.; Sternberg, C. N.; Miller, K.; Mulders, P.; Chi, K. N.; Armstrong, A. J.; Hirmand, M.; Selby, B.; Scher, H. I. |
| Abstract Title: | Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor |
| Meeting Title: | 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2012 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-05-20 |
| Language: | English |
| ACCESSION: | WOS:000318009802767 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2012.30.15_suppl.4519 |
| Notes: | Meeting Abstract: 4519^ -- Source: Wos |
